Dr. Shuvomoy Banerjee is an accomplished academic and researcher with extensive experience as an editorial board member for several reputable journals, including Reviews in Medical Virology, and as an associate editor for the IAR University Journal. He holds a Ph.D. in cancer biology from Bose Institute, Kolkata, and has post-doctoral research experience at the University of Pennsylvania and Beckman Research Institute. Currently an Assistant Professor at the Institute of Advanced Research, Gandhinagar, Dr. Banerjee specializes in cancer immunology and tumor virology. His prolific contributions include numerous publications in high-impact journals. He has led multiple extramural research projects funded by organizations such as the Science and Engineering Research Board (SERB) and the Gujarat State Biotechnology Mission. His active participation in various scientific organizations underscores his credibility and thought leadership in the field of cancer research.Regenerate response Dr. Dhiraj Bhatia, an associate professor at IIT-Gandhinagar, specializes in DNA nanotechnology, chemical biology, and drug delivery systems. With a Ph.D. from NCBS-TIFR and postdoctoral work including an HFSP fellowship at Institut Curie, he has pioneered research in structural DNA nanotechnology for biomedical applications. His publications in high-impact journals like ACS Nano, Nature Nanotechnology, and Angewandte Chemie showcase his expertise. His work on programmable DNA nanodevices, hydrogels, and targeted drug delivery addresses critical challenges such as cancer chemoresistance. Recognized with awards like the Merck Young Scientist Award and INYAS-INSA Membership, Dr. Bhatia is also an experienced reviewer and mentor, actively organizing interdisciplinary conferences

• 1. Exploring chemoresistance mechanisms and innovative drug delivery approaches in effective cancer therapy2. Molecular interplay of hypoxia, aberrant angiogenesis, and immune suppression in cancer chemoresistance3. Impact of hypoxia, angiogenesis, and immunosuppression in chemoresistance4. Design and applications of smart biomaterials for anticancer drug delivery systems5. Revolutionizing precision oncology: Combating chemoresistance with nanorobotics6. Advanced drug delivery strategies: Nanoparticles, liposomes, dendrimers, and smart biomaterials7. Epigenetic modulations in cancer chemoresistance: Harnessing nanotechnology for targeted therapy8. Advancements in cancer immunotherapy: Targeting the tumor immune microenvironment (TIME)9. Near-infrared responsive photothermal-immunotherapy for overcoming chemoresistance in cancer therapy10. Combating chemoresistance through RNA-based therapeutic approaches: A mechanistic insight11. Therapeutic potential of drug repurposing in reversing chemoresistance12. Ion channels in chemoresistance: A mechanistic overview and CRISPR-based therapeutic strategies13. CRISPR/Cas9 and gene editing approaches as a solution for chemoresistance14. Clinical applications and emerging challenges of novel drug delivery systems15. Exosome and extracellular vesicle-based therapeutics to overcome cancer chemoresistance16. Preclinical strategies for investigating drug delivery platforms17. Artificial intelligence and machine learning approaches in rational drug design to overcome cancer chemoresistance18. Chemoresistance in modern oncology: A multilayered network of signaling, plasticity, and tumor microenvironmental interactions

Dr. Shuvomoy Banerjee is an accomplished academic and researcher with extensive experience as an editorial board member for several reputable journals, including Reviews in Medical Virology, and as an associate editor for the IAR University Journal. He holds a Ph.D. in cancer biology from Bose Institute, Kolkata, and has post-doctoral research experience at the University of Pennsylvania and Beckman Research Institute. Currently an Assistant Professor at the Institute of Advanced Research, Gandhinagar, Dr. Banerjee specializes in cancer immunology and tumor virology. His prolific contributions include numerous publications in high-impact journals. He has led multiple extramural research projects funded by organizations such as the Science and Engineering Research Board (SERB) and the Gujarat State Biotechnology Mission. His active participation in various scientific organizations underscores his credibility and thought leadership in the field of cancer research.Regenerate response Dr. Dhiraj Bhatia, an associate professor at IIT-Gandhinagar, specializes in DNA nanotechnology, chemical biology, and drug delivery systems. With a Ph.D. from NCBS-TIFR and postdoctoral work including an HFSP fellowship at Institut Curie, he has pioneered research in structural DNA nanotechnology for biomedical applications. His publications in high-impact journals like ACS Nano, Nature Nanotechnology, and Angewandte Chemie showcase his expertise. His work on programmable DNA nanodevices, hydrogels, and targeted drug delivery addresses critical challenges such as cancer chemoresistance. Recognized with awards like the Merck Young Scientist Award and INYAS-INSA Membership, Dr. Bhatia is also an experienced reviewer and mentor, actively organizing interdisciplinary conferences

• 1. Exploring chemoresistance mechanisms and innovative drug delivery approaches in effective cancer therapy2. Molecular interplay of hypoxia, aberrant angiogenesis, and immune suppression in cancer chemoresistance3. Impact of hypoxia, angiogenesis, and immunosuppression in chemoresistance4. Design and applications of smart biomaterials for anticancer drug delivery systems5. Revolutionizing precision oncology: Combating chemoresistance with nanorobotics6. Advanced drug delivery strategies: Nanoparticles, liposomes, dendrimers, and smart biomaterials7. Epigenetic modulations in cancer chemoresistance: Harnessing nanotechnology for targeted therapy8. Advancements in cancer immunotherapy: Targeting the tumor immune microenvironment (TIME)9. Near-infrared responsive photothermal-immunotherapy for overcoming chemoresistance in cancer therapy10. Combating chemoresistance through RNA-based therapeutic approaches: A mechanistic insight11. Therapeutic potential of drug repurposing in reversing chemoresistance12. Ion channels in chemoresistance: A mechanistic overview and CRISPR-based therapeutic strategies13. CRISPR/Cas9 and gene editing approaches as a solution for chemoresistance14. Clinical applications and emerging challenges of novel drug delivery systems15. Exosome and extracellular vesicle-based therapeutics to overcome cancer chemoresistance16. Preclinical strategies for investigating drug delivery platforms17. Artificial intelligence and machine learning approaches in rational drug design to overcome cancer chemoresistance18. Chemoresistance in modern oncology: A multilayered network of signaling, plasticity, and tumor microenvironmental interactions

Dr. Shuvomoy Banerjee is an accomplished academic and researcher with extensive experience as an editorial board member for several reputable journals, including Reviews in Medical Virology, and as an associate editor for the IAR University Journal. He holds a Ph.D. in cancer biology from Bose Institute, Kolkata, and has post-doctoral research experience at the University of Pennsylvania and Beckman Research Institute. Currently an Assistant Professor at the Institute of Advanced Research, Gandhinagar, Dr. Banerjee specializes in cancer immunology and tumor virology. His prolific contributions include numerous publications in high-impact journals. He has led multiple extramural research projects funded by organizations such as the Science and Engineering Research Board (SERB) and the Gujarat State Biotechnology Mission. His active participation in various scientific organizations underscores his credibility and thought leadership in the field of cancer research.Regenerate response Dr. Dhiraj Bhatia, an associate professor at IIT-Gandhinagar, specializes in DNA nanotechnology, chemical biology, and drug delivery systems. With a Ph.D. from NCBS-TIFR and postdoctoral work including an HFSP fellowship at Institut Curie, he has pioneered research in structural DNA nanotechnology for biomedical applications. His publications in high-impact journals like ACS Nano, Nature Nanotechnology, and Angewandte Chemie showcase his expertise. His work on programmable DNA nanodevices, hydrogels, and targeted drug delivery addresses critical challenges such as cancer chemoresistance. Recognized with awards like the Merck Young Scientist Award and INYAS-INSA Membership, Dr. Bhatia is also an experienced reviewer and mentor, actively organizing interdisciplinary conferences

• 1. Exploring chemoresistance mechanisms and innovative drug delivery approaches in effective cancer therapy2. Molecular interplay of hypoxia, aberrant angiogenesis, and immune suppression in cancer chemoresistance3. Impact of hypoxia, angiogenesis, and immunosuppression in chemoresistance4. Design and applications of smart biomaterials for anticancer drug delivery systems5. Revolutionizing precision oncology: Combating chemoresistance with nanorobotics6. Advanced drug delivery strategies: Nanoparticles, liposomes, dendrimers, and smart biomaterials7. Epigenetic modulations in cancer chemoresistance: Harnessing nanotechnology for targeted therapy8. Advancements in cancer immunotherapy: Targeting the tumor immune microenvironment (TIME)9. Near-infrared responsive photothermal-immunotherapy for overcoming chemoresistance in cancer therapy10. Combating chemoresistance through RNA-based therapeutic approaches: A mechanistic insight11. Therapeutic potential of drug repurposing in reversing chemoresistance12. Ion channels in chemoresistance: A mechanistic overview and CRISPR-based therapeutic strategies13. CRISPR/Cas9 and gene editing approaches as a solution for chemoresistance14. Clinical applications and emerging challenges of novel drug delivery systems15. Exosome and extracellular vesicle-based therapeutics to overcome cancer chemoresistance16. Preclinical strategies for investigating drug delivery platforms17. Artificial intelligence and machine learning approaches in rational drug design to overcome cancer chemoresistance18. Chemoresistance in modern oncology: A multilayered network of signaling, plasticity, and tumor microenvironmental interactions